Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma.

OBJECTIVE

To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas.

DESIGN

Case control study based on retrospective medical record review.

SETTING

A tertiary care comprehensive cancer center.

PATIENTS

A total of 24 patients, 12 with major salivary gland carcinoma who were treated with postoperative concurrent chemoradiotherapy from 1998 to 2007 (chemoradiation group), and a control group of 12 patients treated with postoperative radiation alone.

MAIN OUTCOME MEASURES

Overall survival, progression-free survival, toxic effects.

RESULTS

All but 1 patient had stage III or IV disease; close or positive surgical margins were identified in 20 patients (83%). The median radiation dose was 63 Gy. In the chemoradiation group, platinum-based regimens were used in all. Treatment was well tolerated, but toxic effects, predominantly hematologic, were increased in the chemoradiation group. To date, 8 patients have died; the median overall survival was 53 months. The overall survival in the chemoradiation group was significantly better than in the radiation-alone group: 3-year survival rates were 83% and 44%, respectively (P = .05).

CONCLUSIONS

Locally advanced or high-grade salivary gland carcinomas follow an aggressive clinical course. Based on our limited experience, postoperative chemoradiation with a platinum-based regimen seems to be effective in selected patients and warrants further investigation.